Finn Stockinger@FinnStockinger
A +160% Revenue Jump Ahead? Why $AEHR Aehr Test Systems Just Sparked a Massive Stock Surge
If you were waiting for proof that Aehr Test Systems has officially put its cycle downturn in the rearview mirror, this Q4 and full-year FY2026 earnings report was it.
The stock didn't just react - it exploded upward after the release, and looking closely at the fundamentals, Wall Street’s aggressive re-rating makes absolute sense.
This isn't just a minor beat; it’s a textbook turnaround for a specialized equipment maker hitting its production-scaling sweet spot.
Here is my breakdown of the hard numbers and what they mean for the business going forward.
1. Q4 FY2026: A Clean Pivot Back to Profitability
> Revenue:
$18.8 million, up 33% YoY (compared to $14.1M in Q4 FY25). Comfortably beating consensus estimates hovering around $17.9M.
> GAAP Net Income:
$1.4 million ($0.04 per share), flipping from a GAAP net loss of $2.9 million in the prior-year period.
> Non-GAAP Net Income:
$3.6 million ($0.11 per share).
Beyond top-line growth, look at the balance sheet: cash, cash equivalents, and restricted cash shot up to $116.5 million (up from $37.1 million a quarter earlier), largely bolstered by strategic capital raises.
For a small-cap hardware vendor, this massive liquidity buffer is critical.
It provides Aehr with the necessary runway to fund working capital and scale inventory for massive incoming orders without needing additional financing anytime soon.
2. The Backlog: The Real Catalyst Behind the Rally
The quarter’s top-line beat was nice, but the skyrocketing order intake is why the stock took off:
> Q4 Bookings:
A record-breaking $60.7 million secured in a single quarter.
> Effective Backlog:
Ending backlog at fiscal year-end sat at $80.6 million, but when factoring in orders received immediately post-quarter, the effective backlog topped $100.6 million.
In the wafer-level burn-in and test industry, moving from customer evaluation units to volume production tool orders is where the real multi-year growth inflection happens.
That inflection is clearly happening right now.
3. Full-Year FY2026: Weak Start, Strong Finish
> Annual Revenue:
$50.0 million (down from $59.0 million in FY2025).
> GAAP Net Loss:
$7.1 million for the full year.
> Non-GAAP Net Income:
$0.9 million.
Judging Aehr on its full-year loss would be missing the forest for the trees.
The full-year numbers reflect the severe cyclical slump in EV-related silicon carbide (SiC) demand from late 2024 and early 2025.
That trough is now firmly behind them, as evidenced by the Q4 trajectory.
4. FY2027 Guidance: Tripling the Top Line?
Management delivered extremely aggressive, confident guidance for the upcoming fiscal year 2027:
> Revenue Guidance:
$130 million to $150 million (representing ~160% to 200% YoY growth).
> Non-GAAP Net Margin:
Projected at 18% to 22% of revenues.
Targeting up to $150M in revenue is bold, but with over $100M already in effective backlog, it is grounded in real demand.
The bottleneck now shifts from sales demand to supply chain execution.
To justify the post-earnings stock price pop, Aehr must build and ship its FOX-XP systems on schedule without manufacturing delays or gross margin erosion.
Key Takeaways for Investors 👇
Now that the stock has run up post-earnings, the market has priced in high expectations.
Moving forward, keep a close eye on two things:
> Quarterly execution vs. run-rate:
Consistent sequential revenue ramps toward that $130M–$150M target.
> Margin discipline:
GAAP vs. Non-GAAP delta, particularly around stock-based compensation (SBC).
Aehr proved it can weather a semiconductor slowdown.
Now, it enters the execution phase of its scaling strategy.
